A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Biochemical Pharmacology

• Publication date

  2011-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bcp.2011.02.009PMID 21371447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• W1103 Mechanism of Inhibition of the Gastric H+,K+-ATPase by a Novel K+-Competitive Acid Blocker Tak-438

  2010cited by this paper
• 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

  2010cited by this paper
• Proton pump inhibitors: an update of their clinical use and pharmacokinetics

  2008cited by this paper
• The gastric HK-ATPase: structure, function, and inhibition

  2008cited by this paper
• Control of gastric acid secretion in health and disease.

  2008cited by this paper
• A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

  2008cited by this paper
• A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

  2007cited by this paper
• Nocturnal acid breakthrough: Clinical significance and management

  2006cited by this paper
• Acid Suppression Therapy: Where Do We Go from Here?

  2006cited by this paper
• Gastroesophageal reflux disease.

  2005cited by this paper
• Is there a rationale for therapeutic immunoadsorption in multiple sclerosis?

  2005cited by this paper
• Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.

  2005cited by this paper
• Developments in the inhibition of gastric acid secretion

  2005cited by this paper
• Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.

  2004cited by this paper
• CYP2C19 polymorphism and proton pump inhibitors.

  2004cited by this paper
• Divalent cations regulate acidity within the lumen and tubulovesicle compartment of gastric parietal cells.

  2004cited by this paper
• Novel therapeutic strategies in acid-related disorders

  2003cited by this paper
• Role of ADP-ribosylation Factor 6 (ARF6) in Gastric Acid Secretion*

  2003cited by this paper
• Inhibition of carbachol stimulated acid secretion by interleukin 1β in rabbit parietal cells requires protein kinase C

  2001cited by this paper
• Phosphatidylinositol is essential determinant for K+ permeability involved in gastric proton pumping.

  2001cited by this paper
• Vesicular trafficking machinery, the actin cytoskeleton, and H+-K+-ATPase recycling in the gastric parietal cell.

  2001cited by this paper
• Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazole

  2000cited by this paper
• Studies on the mechanism of action of the gastric H+,K(+)-ATPase inhibitor SPI-447.

  2000cited by this paper
• Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

  1998cited by this paper
• Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.

  1995cited by this paper
• Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.

  1990cited by this paper
• Primary culture of secretagogue-responsive parietal cells from rabbit gastric mucosa.

  1989cited by this paper
• Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

  1989cited by this paper
• Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole.

  1987cited by this paper
• Stimulation-associated redistribution of H+-K+-ATPase activity in isolated gastric glands.

  1987cited by this paper
• Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.

  1987cited by this paper
• Gastric antisecretory and cytoprotective activities of SCH 28080.

  1983cited by this paper
• Forskolin stimulation of acid and pepsinogen secretion in isolated gastric glands.

  1983cited by this paper
• A STUDY OF THE INHIBITORY EFFECTS OF SCH 28080 ON GASTRIC SECRETION IN MAN

  1982cited by this paper
• Effects of secretagogues on oxygen consumption, aminopyrine accumulation and morphology in isolated gastric glands.

  1976cited by this paper
• A method for preparing isolated glands from the rabbit gastric mucosa.

  1976cited by this paper
• THE COLORIMETRIC DETERMINATION OF PHOSPHORUS

  1925cited by this paper

• Efficacy of Vonoprazan in Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer in Terms of Ulcer Recurrence and Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis

  2025cites this paper
• The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study

  2025cites this paper
• The Effect of Tegoprazan on Serum Gastrin Levels and the Development of Hypergastrinemia in the Maintenance Treatment for Gastroesophageal Reflux Disease: Comparison to Lansoprazole

  2025cites this paper
• Comparison of the preventive effects of proton pump inhibitors and vonoprazan on delayed bleeding after gastric endoscopic submucosal dissection

  2025cites this paper
• Pharmacovigilance of Vonoprazan: a Review of Safety and Adverse Event Profiles

  2025cites this paper
• Insights into tumor-derived exosome inhibition in cancer therapy.

  2025cites this paper
• Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis

  2024cites this paper
• Endoscopic findings and outcomes of gastric mucosal changes relating to potassium‐competitive acid blocker and proton pump inhibitor therapy

  2024cites this paper
• Efficacy and Safety of Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors in Treating Erosive Esophagitis

  2024cites this paper
• Seven‐Day Vonoprazan‐Based Triple Therapy as First‐Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial

  2024cites this paper
• Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers.

  2024cites this paper
• Amelioration of obsessive-compulsive disorder by intracellular acidification of cortical neurons with a proton pump inhibitor

  2024cites this paper
• 헬리코박터 파일로리 제균 치료의 새로운 치료법으로서의 칼륨 경쟁적 위산분비 차단제

  2023cites this paper
• Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.

  2023cites this paper
• Progress in the Study of Vonoprazan Fumarate vs. Proton Pump Inhibitors in the Treatment of Gastroesophageal Reflux Disease

  2023cites this paper
• JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases

  2023cites this paper
• Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis

  2023cites this paper
• Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder

  2023cites this paper
• Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy

  2023cites this paper
• Development of a patient-centric formulation of tegoprazan, a novel potassium-competitive acid blocker, using modified-release drug-coated pellets

  2022cites this paper
• Identification, characterization, synthesis of major metabolites biotransformed from vonoprazan fumarate

  2022cites this paper
• Vonoprazan on the Eradication of Helicobacter pylori Infection

  2022cites this paper
• Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study

  2022cites this paper
• The role of vonoprazan in patients with erosive esophagitis

  2022cites this paper
• Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.

  2022cites this paper
• Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies

  2021cites this paper
• The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

  2021cites this paper
• Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial

  2021influential citation
• High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions

  2021cites this paper
• Gastroprotective Effects of Spirulina platensis, Golden Kiwifruit Flesh, and Golden Kiwifruit Peel Extracts Individually or in Combination against Indomethacin-Induced Gastric Ulcer in Rats

  2021cites this paper
• Effects of vonoprazan on gastric PH and clinical course after gastric ESD: A retrospective and prospective study

  2020cites this paper
• Propensity score matching analysis: incidence and risk factors for “stardust” gastric mucosa, a novel gastric finding potentially induced by vonoprazan

  2020cites this paper
• Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

  2020cites this paper
• Vonoprazan Versus Lansoprazole in the Treatment of Artificial Gastric Ulcers After Endoscopic Submucosal Dissection: a Randomized Controlled Trial

  2020influential citation
• The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease

  2020cites this paper
• Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease

  2020cites this paper
• Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.

  2020cites this paper
• Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer

  2020cites this paper
• Physiologically based pharmacokinetic–pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans

  2020cites this paper
• Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

  2019cites this paper
• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

  2019cites this paper
• Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux

  2019cites this paper
• Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD

  2019cites this paper
• Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis

  2019cites this paper
• Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis

  2019cites this paper
• A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia

  2019influential citation
• A Pilot Study on Evaluating the Efficacy of Vonoprazan and Acotiamide in Patients with Functional Dyspepsia Overlapping Reflux Symptoms

  2018cites this paper
• Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?

  2018cites this paper
• Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

  2018cites this paper
• New pharmacological treatments for gastroesophageal reflux: Potassium-competitive acid blockers and bile acid sequestrants

  2018cites this paper
• Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers

  2018cites this paper
• Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

  2018cites this paper
• Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers

  2018cites this paper
• Embryo–fetal toxicity assessment of vonoprazan in rats and rabbits

  2018cites this paper
• Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis

  2018cites this paper
• Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

  2018cites this paper
• Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children

  2018cites this paper
• Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?

  2018cites this paper
• Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori.

  2018cites this paper
• [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].

  2018cites this paper
• Potassium-competitive Acid Blocker-based Therapy for Helicobacter pylori Eradication

  2017cites this paper
• A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

  2017cites this paper
• Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post‐endoscopic submucosal dissection: A propensity score‐matching analysis

  2017cites this paper
• The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors

  2017cites this paper
• Vonoprazan fumarate for the management of acid-related diseases

  2017cites this paper
• Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.

  2017cites this paper
• Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs

  2017influential citation
• In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

  2017cites this paper
• Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study

  2017cites this paper
• A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.

  2017cites this paper
• Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients

  2017cites this paper
• Novel and practical synthesis of vonoprazan fumarate

  2017cites this paper
• Pulmonary , gastrointestinal and urogenital pharmacology KFP-H 008 blocks gastric acid secretion through inhibiting H +-K +-ATPase

  2017cites this paper
• Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

  2016cites this paper
• The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

  2016cites this paper
• Toll-like receptor 9 modifies intestinal serotonergic system.

  2016cites this paper
• Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.

  2016cites this paper
• Effects of potassium diformate on the gastric function of weaning piglets

  2016cites this paper
• Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa

  2016cites this paper
• Pharmacologic Management of Nonvariceal Upper Gastrointestinal Bleeding

  2016cites this paper
• A New Effective Therapy for Helicobacter pylori Eradication Using a Potassium-Competitive Acid Blocker

  2016cites this paper
• Vonoprazan: MarKed Competition for PPIs?

  2016cites this paper
• Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations

  2016cites this paper
• Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.

  2016cites this paper
• Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)

  2016cites this paper
• Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

  2016cites this paper
• Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate.

  2016cites this paper
• A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry.

  2016cites this paper
• Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

  2016influential citation
• A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.

  2016cites this paper
• The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

  2016cites this paper
• Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials

  2016cites this paper
• [Pharmacological and clinical profiles of a novel potassium-competitive acid blocker, vonoprazan fumarate (Takecab(®) 10 mg and 20 mg)].

  2015cites this paper
• Anti-ulcer agents: chemical aspect of solving the problem

  2015cites this paper
• Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

  2015cites this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

  2015cites this paper
• Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

  2015cites this paper
• Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

  2015cites this paper
• Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

  2015cites this paper
• Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers

  2014cites this paper